Genocea Biosciences is harnessing the power of T cell immunity to develop the next generation of vaccines. T cells are increasingly recognized as a critical element of a protective immune response to a wide range of infectious disease pathogens, but are difficult to target using traditional vaccine discovery methods. Genocea is uniquely able to identify protective T cell antigens in humans exposed to a pathogen using ATLAS™, its proprietary technology platform that mimics the human immune response in the laboratory, potentially improving the effectiveness of vaccine candidates and drastically reducing the time needed to create them. Genocea's pipeline of novel T cell vaccines includes GEN-003 for HSV-2 therapy, currently in a Phase 1/2a trial, GEN-004, a protein vaccine directed at pneumococcus that is expected to enter the clinic in the fourth quarter of 2013, and earlier-stage programs in chlamydia, HSV-2 prophylaxis and malaria. Learn more
Technology > More
12.05.13: Genocea Biosciences Initiates Phase 1 Study of Vaccine Candidate GEN-004 to Prevent Infections Caused By Pneumococcus…more »
11.18.13: Genocea Biosciences Appoints Katrine Bosley as Chairman of The Board Of Directors; Vaccine Industry Leader George Siber, M.D. To Serve As Executive Director and Head of Scientific Advisory Board… more »
09.12.13: Genocea Reports Positive Initial Phase 1/2a Results for Gen-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (Hsv-2), at ICAAC 2013… more »
For more information on our clinical trial, please see http://clinicaltrials.gov/ct2/results?term=gen-003.